Verde Science Inc. (VRCI)
EXPM EXPM Primary 
XSTU 
Verici Dx gains Olink Certified Service Provider status to expand proteomics offering
Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. The certification, part of Thermo Fisher's Life Sciences Solutions network, enables Verici Dx to support biomarker discovery, algorithm development, validation, clinical trials and diagnostic applications for both external clients and its own development pipeline.
Verici Dx rises after passing key US laboratory accreditation audit
Verici Dx PLC (AIM:VRCI) shares were up as much as 11% in early trading after the diagnostics company announced it had successfully completed its second biennial inspection by the College of American Pathologists (CAP), one of the leading US bodies for clinical laboratory accreditation. The inspection passed with no deficiencies, confirming the company's continued compliance with CAP's rigorous quality and operational standards.
Verici Dx climbs on 'preferred provider' deal with US healthcare network
Verici Dx PLC (AIM:VRCI) shares skipped 12% higher to 0.7p after the developer of diagnostic tests for organ transplants bagged a new agreement with a healthcare network in the United States. The deal with Prime Health Services sees Verici Dx join a preferred provider network, giving its services access to more than 850,000 healthcare providers and 35 million insurance claims a year.
Verici Dx shares jump 23% as transplant test rollout gathers pace
Shares in Verici Dx PLC (AIM:VRCI) surged 23% in early trading on Monday after the diagnostics company reported encouraging progress in the commercial rollout of its Tutivia test for kidney transplant patients and announced changes to its board. The London-listed group said it had onboarded nine new transplant centres in the United States during the third quarter, taking the total to 30.
Verici Dx plans fresh funding round to boost US test rollout
Verici Dx PLC (AIM:VRCI) is preparing to raise new equity funding as it looks to ramp up the commercial rollout of its flagship transplant diagnostic, Tutivia, in the US following a key Medicare coverage decision. The London-listed diagnostics firm said it had received early support from institutional backers and other investors for the planned fundraising, which will include a placing and a retail offer for existing shareholders.
Verici Dx says its seen a significant increase in Tutivia orders
Verici Dx PLC (AIM:VRCI) told investors it has seen a significant increase in Tutivia test orders during the first quarter. The company, which has an RNA-based test used by patients before kidney transplants, said it had 292 orders – up 68% increase from the previous quarter, and compared to 334 orders in all of 2024.
